Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP10728558.7Aexternal-prioritypatent/EP2448933B1/en
Application filed by Eli Lilly And CompanyfiledCriticalEli Lilly And Company
Publication of CY1114514T1publicationCriticalpatent/CY1114514T1/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
Αποκαλύπτονται ενώσεις του τύπου του τίτλου, trans-4-[[(5S)-5-[[[3,5-δις(τριφθορομεθυλ)φαινυλ]μεθυλ](2-μεθυλ-2Η-τετραζολ-5-υλ)αμινο]-2,3,4,5-τετραϋδρο-7,9-διμεθυλ-1Η-1-βενζαζεπιν-1-υλ]μεθυλ]-κυκλοεξανοκαρβοξυλικό οξύ, ως ελεύθερο οξύ ή φαρμακευτικώς αποδεκτό άλας αυτού, υδρίτης και υδρίτης σε κρυσταλλική μορφή, φαρμακευτικές συνταγοποιήσεις και μέθοδοι χρήσης.Trans-4 - [[(5S) -5 - [[[3,5-bis (trifluoromethyl) phenyl] methyl] (2-methyl-2H-tetrazol-5-yl) amino] - compounds of title are disclosed 2,3,4,5-tetrahydro-7,9-dimethyl-1H-1-benzazepin-1-yl] methyl] -cyclohexanecarboxylic acid, as a free acid or a pharmaceutically acceptable salt thereof, hydrate and hydrate in crystalline form, pharmaceutical formulations and methods of use.
Methyl Pharmacy Acceptable Salt (3 - ([[3- (6-amino-2-butoxi-8-oxo-7,8-dihydro-9H-purin-9-il) propyl) (3-morpholin-4-ilpropyl) amino) - methyl)-phenyl) acetate And use in the treatment of disease